hemotune AG
- Industry
- Medical Device
- Founded Year
- 2017
- Headquarters
- Wagistrasse 27, 8952 Schlieren, Switzerland
- Employee Count
- 0
Key People
- Lukas Langenegger - CEO and Co-founder
- Dr. Darius Madjdpour - Founder at Belmondo
- Cdric Barra - Senior Investment Manager at OCCIDENT
- Dr. Annick Bay - Senior Associate of VP Venture Partners
- Pascal Winnen - CEO of HEMEX
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises experienced professionals with over a decade in their respective fields.
The leadership team's background and experience are crucial for navigating the complexities of the MedTech industry and bringing innovative products to market.
- Clinical Need
-
Aspect: Very Strong
Summary: The HemoSystem addresses the critical need for effective sepsis treatment, a condition responsible for approximately 11 million deaths annually.
Sepsis is a major global health issue with high mortality rates and limited effective treatments. The HemoSystem's targeted approach offers a promising solution to this pressing problem.
- Competition
-
Aspect: First mover
Summary: Hemotune's HemoSystem introduces a novel approach to blood purification, positioning the company as a first mover in this space.
The innovative use of nanoengineered magnetic beads for blood purification sets hemotune apart from existing solutions, offering a unique value proposition in the MedTech industry.
- Technical Challenge
-
Aspect: Complex
Summary: Developing and implementing the HemoSystem involves complex engineering and biomedical challenges.
The integration of nanotechnology with medical devices requires rigorous testing, validation, and compliance with stringent regulatory standards, which can extend development timelines and increase costs.
- Patent
-
Aspect: Very Strong
Summary: Hemotune holds a robust intellectual property portfolio, including worldwide exclusive licenses and patents on device assembly and treatment strategies.
A comprehensive patent portfolio safeguards the company's innovations, deterring competitors and providing leverage in strategic partnerships and funding negotiations.
- Financing
-
Aspect: Well-funded
Summary: Hemotune has successfully raised significant funding, including a CHF 14 million Series B2 round, indicating strong investor confidence.
The substantial financial backing enables the company to advance its technology through critical development phases, including preclinical and clinical trials, without immediate financial constraints.
- Regulatory
-
Aspect: Running FIH
Summary: Hemotune is preparing to enter first-in-human (FIH) clinical trials for the HemoSystem.
While entering FIH trials is a significant milestone, the outcomes are uncertain, and subsequent phases will require successful results to achieve regulatory approval and market entry.
Opportunity Rollup
- Odds of Success
- 3.95
- Peak Market Share
- 5.9
- Segment CAGR
- 9.4%
- Market Segment
- Blood Purification Devices
- Market Sub Segment
- Sepsis Treatment
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.30 |
| 2 | 0.88 |
| 3 | 2.06 |
| 4 | 4.13 |
| 5 | 5.90 |
Key Takeaway
Hemotune's innovative HemoSystem addresses a critical unmet need in sepsis treatment, supported by strong IP and funding, but faces technical and regulatory challenges ahead.